While representing our clients, we dig deep into drug company files to discover the truth about what the company knew about the drug’s risks, when the company knew of those risks and what efforts, if any, the company took to hide those risks. Only through legal action can anyone gain access to this type of information.
Our lawyers are also strong public health advocates. Baum Hedlund attorneys have testified on several occasions at FDA drug safety hearings and have met with several members of the U.S. House and Senate. Many of our attorneys have delivered Continuing Legal Education accredited lectures and written articles on the many complex issues involved in pharmaceutical litigation. Our law firm has also assisted investigators in a number of Congressional investigations.
Past efforts by Baum Hedlund and others have resulted in improvements in drug safety including the most recent FDA black box suicide warning issued on certain antidepressants. The firm’s efforts get innocent victims compensated when duties are neglected or willfully disregarded.
Baum Hedlund has been on the prevailing side of some of the nation’s most highly-publicized cases. Such litigation involves complex evidence and choice of law issues which have been routinely handled by the firm in both state and federal courts. Many of our attorneys have delivered Continuing Legal Education accredited lectures and written articles on the many complex issues involved in pharmaceutical litigation. Baum Hedlund is accustomed to handling the simplest and most complex cases and is here to solve legal problems caused by negligent conduct.
Over the past two decades, Baum Hedlund has been handling SSRI-induced suicide/violence litigation involving Prozac, Paxil and Zoloft. The firm is more recently handling SSRI related PPHN, heart birth defect and autism cases. We have the longest track-record handling SSRI antidepressant litigation, having litigated thousands of antidepressant cases. Baum Hedlund was appointed Lead Counsel for the Plaintiffs’ Steering Committee (MDL-1574) Paxil Products Liability Litigation and has been on the plaintiffs steering committees on a number of other pharmaceutical multi-district litigation cases including the Heparin Products Liability Litigation, the Consolidated Complex Biological-Medical Products Liability Cases and the Fialuridine Product Liability Cases.
Baum Hedlund lawyers have successfully defeated arguments by drug-makers and the FDA, that cases involving FDA-approved drugs should be federally preempted in a number of cases such as Knipe v. SmithKline Beecham d/b/a GlaxoSmithKline, Tucker v. SmithKline Beecham, Corporation, Collins v. SmithKline Beecham Corporation, Case No. 00762 (Court of Common Pleas, Philadelphia County, March 11, 2008), Steinberg v. SmithKline Beecham Corp. Case No. 104CV029096 (Santa Clara Sup. Ct., January 25, 2007), Witczak v. Pfizer, 377 F.Supp.2d 726 (D. Minn 2005); Zikis v. Pfizer, Inc., WL 1126909 (N.D. Ill. 2005); Cartwright v. Pfizer, Inc., 369 F.Supp.2d 876 (E.D. Tex. 2005); Miles v. Pfizer, Inc., Case No. 03731C (M.D. La. March 31, 2005) (order without opinion); Szybinski v. Pfizer, Inc., Case No. YC 047439 (Los Angeles Sup. Ct. July 12, 2005) (minute order striking FDA Amicus Briefs and denying preemption), and; Motus v. Pfizer, 137 F. Supp. 2d 1085 (C.D. Cal., 2000).
We take pride in creating coalitions of activists, attorneys and Baum Hedlund staff that work together to resolve global problems caused by harmful drugs and products, which no individual could accomplish alone.
Rigorously investigating and litigating the types of devastating drug injury and death cases we handle on a daily basis requires relentless focus and dedication to our clients’ causes. We are tenacious and unflinching when it comes to seeking evidence and have routinely prevailed in both state and federal courts.